{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-25-000097","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.272463+00:00","generated_at":"2026-05-16T13:06:19.708683+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Inhibrx provides INBRX-106 and ozekibart trial updates; Ewing sarcoma FDA meeting planned for H2 2026","bullets":["INBRX-106 HNSCC Phase 2/3: 46 of 60 patients enrolled; completion expected Q1 2026.","NSCLC Phase 1/2 trial completed enrollment of 34 patients in Nov 2025; data immature.","Ozekibart colorectal cancer expansion cohort enrolled 44 patients; PFS data mature Q2 2026.","Ewing sarcoma trial enrollment expected Q2 2026; FDA meeting for accelerated approval planned H2 2026 if trends continue.","No efficacy data released; management cautions datasets lack maturity for conclusions."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-25-000097","json":"https://secwatch.observer/filing/0002007919-25-000097.json","markdown":"https://secwatch.observer/filing/0002007919-25-000097.md","text":"https://secwatch.observer/filing/0002007919-25-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/0002007919-25-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791925000097/inhibrx-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:06:19.708683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}